The pharma ingredients provider discusses new products, supply-chain obstacles, and what the future of the industry might hold, ahead of the online event.
A leader from the scientific software provider discusses the most challenging obstacles in the pharma supply chain, and solutions that can conquer them.
An executive from Pharmaceutical Associates Inc. believes bringing drug manufacturing back to the country will help avoid shortages and other disasters.
The imaging company’s newly launched division, created to produce drug ingredients, received the loan from the US International Development Finance Corp.
The ninth annual event, taking place in Boston mid-November, will feature industry professionals addressing manufacturing practices, regulatory updates and market trends.
The two firms are joining forces to develop AI-based technology for continuous manufacturing of critical APIs necessary for producing crucial small-molecule drugs.
Apprentice is sending sets of technology tools to pharmaceutical research and manufacturing facilities, including its Tandem AR collaboration platform.
Genentech enters a manufacturing and development agreement with Enable Injections to advance the latter’s patient-administered subcutaneous drug delivery system.
Samsung Biologics and UCB agree to an additional drug substance manufacturing deal to produce an anti-tau candidate currently in Phase I clinical trials to treat progressive supranuclear palsy.
Growing need for validated storage capacity sees Lyophilization Services of New England complete an expansion its cGMP storage capabilities at its New Hampshire site.
Merck to invest in its North Carolina facilities as it expands production capacity to meet demand for its HPV vaccine Gardasil, and grow its packaging operations
Lonza to use Rockwell Automation technology as it digitizes the operations and manufacturing environments at nine of its Capsugel facilities to bring “new levels” of operational efficiency.
The company initiates operations at its new EU headquarters in Dundalk, Ireland after receiving its manufacturing and importation authorization license from the HPRA.
Xellia will move US production from its North Carolina manufacturing facility to its site in Ohio to bolster workforce and manufacture generic IV antibiotics.
Zosano completes site qualification batches for its subcutaneous investigational migraine treatment and readies itself for NDA submission by the end of year.
Lonza expands its HPAPI production capacity at its Switzerland facility after entering an agreement with AstraZeneca, and invests in manufacturing to establish efficiency.
San Diego, CA-based NanoComposix received its drug manufacturing license which it said will ensure clients are able to use one vendor throughout the product life cycle.
